Vγ9Vδ2 T cells as a promising innovative tool for immunotherapy of hematologic malignancies

  • Serena Meraviglia | dieli@unipa.it Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi, Universita` di Palermo, Palermo, Italy.
  • Carmela La Mendola Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi, Universita` di Palermo, Palermo, Italy.
  • Valentina Orlando Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi, Universita` di Palermo, Palermo, .
  • Francesco Scarpa Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi, Universita` di Palermo, Palermo, Italy.
  • Giuseppe Cicero Dipartimento di Discipline Chirurgiche ed Oncologiche, Universita` di Palermo, Palermo, Italy.
  • Francesco Dieli Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi, Universita` di Palermo, Palermo, Italy.

Abstract

The potent anti-tumor activities of γδ T cells, their ability to produce pro-inflammatory cytokines, and their strong cytolytic activity have prompted the development of protocols in which γδ agonists or ex vivo-expanded γδ cells are administered to tumor patients. γδ T cells can be selectively activated by either synthetic phosphoantigens or by drugs that enhance their accumulation into stressed cells as aminobisphosphonates, thus offering new avenues for the development of γδ T cell-based immunotherapies. The recent development of small drugs selectively activating Vγ9Vδ2 T lymphocytes, which upregulate the endogenous phosphoantigens, has enabled the investigators to design the experimental approaches of cancer immunotherapies; several ongoing phase I and II clinical trials are focused on the role of the direct bioactivity of drugs and of adoptive cell therapies involving phosphoantigen- or aminobisphosphonate-activated Vγ9Vδ2 T lymphocytes in humans. In this review, we focus on the recent advances in the activation/expansion of γδ T cells in vitro and in vivo that may represent a promising target for the design of novel and highly innovative immunotherapy in patients with hematologic malignancies.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2011-12-14
Info
Issue
Section
Reviews
Keywords:
Vc9Vd2 T cells - Hematologic malignancies - Immunotherapy - Cytokines - CytotoxicityVc9Vd2 T cells - Hematologic malignancies - Immunotherapy - Cytokines - Cytotoxicity
Statistics
  • Abstract views: 1329

  • FULL TEXT: 195
How to Cite
Meraviglia, S., La Mendola, C., Orlando, V., Scarpa, F., Cicero, G., & Dieli, F. (2011). Vγ9Vδ2 T cells as a promising innovative tool for immunotherapy of hematologic malignancies. Oncology Reviews, 4(4), 211-218. https://doi.org/10.4081/oncol.2010.67